A data safety monitoring board (DSMB) has recommended that Inventiva continue its Phase 2b clinical trial assessing lanifibranor (previously known as IVA337)…
Articles by Magdalena Kegel
Organ fibrosis in scleroderma patients might be reversed with treatments that allow fibrotic cells to self-destruct, Harvard scientists suggest. Their study,…
Over the past year, Scleroderma News has brought you news on scleroderma therapeutic developments, clinical trials, research, and events. While…
Corbus Pharmaceuticals is planning a global Phase 3 trial to assess anabasum (JBT-101) as a treatment for scleroderma. If…
University of Colorado researchers have discovered a molecule that prevents the activation of a receptor that scientists believe is…
Scleroderma patients’ nerve-related hand problems, including numbness, tingling and pain, may stem from the main nerve to the hands becoming…
Corbus Pharmaceuticals is sharing a host of data on anabasum (JBT-101) for the treatment of diffuse cutaneous scleroderma at the…
Specific autoantibodies may give rise to clear differences in disease features among Spanish patients with scleroderma, according to a report…
Corbus Pharmaceuticals says a Phase 3 clinical trial of anabasum for diffuse cutaneous scleroderma will start in the…
Cytori Therapeutics’ Habeo Cell Therapy may be effective only in scleroderma patients who have the more severe diffuse version…